Advertisement


Alex Andrea Francoeur, MD, on Endometrial Cancer and Obesity Trends

2024 ASCO Annual Meeting

Advertisement

Alex Andrea Francoeur, MD, of UC Irvine Health, discusses data showing an association between the increasing incidence of endometrial cancer and obesity, which disproportionately affects younger women and women of color. According to Dr. Francoeur, the findings warrant targeted health services and public health interventions to stabilize and ultimately reverse the rising rates (Abstract 5507).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Obesity has been identified to be a risk factor for endometrial cancer, but trends overtime have not been well studied. So the objective of our study was to study the trends of endometrial cancer and obesity from 2001 to 2018 in the United States using a large national database. Additionally, we aim to identify people most at risk based on these findings and identify disparities on a population-based level. For this study, we used the United States Cancer Statistics Database to gather data on endometrial cancer. This database represents over 99% of all cancer cases diagnosed in the United States. We then performed a correction for hysterectomy and pregnancy within this database. For data on obesity, we used the NHANES database, which provides population-based statistics on obesity for the United States. To compare the relationship in trends between endometrial adenocarcinoma and obesity, a Pearson correlation coefficient was calculated for selected groups. We identified 586,000 cases of endometrioid adenocarcinoma from 2001 to 2018. When looking at our obesity data, the majority of the US female population is either overweight or obese. And the majority of Black and Hispanic women are overweight or obese. Endometrioid adenocarcinoma rates are increasing in younger age groups. In the 20 to 29 year old age group, we found that there's been a 137% increase in the rate of endometrial adenocarcinoma since 2001. In the 30 to 39 year old age group, we found that there's been a 71% increase. When looking at trends by race and ethnicity, we found that in Black women, there's been an increase in endometrial cancers of 25% since 2001, and in Hispanic women, there's been an increase of 17%. We then performed a trend analysis of obesity and endometrial cancer in parallel. Rates of obesity are rising at 7.5% in the 20 to 29 year old age group per year. The highest rate of increase in any age group. Rates of endometrial cancer are rising in this age group at 4.5% per year, also the highest of any age group. The correlation coefficient for this age group was 0.78, demonstrating a strong correlation. We see a similar trend in women age 30 to 39 with rates of obesity rising at 4.5% annually, and rates of cancer rising at 3% per year. Again, demonstrating a strong correlation with an R of 0.88. We see similar trends when we look at race and ethnicity, where obesity and endometrioid adenocarcinoma are statistically significantly correlated. In conclusion, the current data, although retrospective, demonstrate a strong temporal association in the rising rates of obesity and endometrioid adenocarcinoma in the United States. This represents a public health emergency, and actions are needed to address the impact of obesity on endometrial cancer. These actions can include increased awareness, medications, targeting weight management, surgical management of obesity, and increased research in this area.

Related Videos

Leukemia
Immunotherapy

Allison M. Winter, MD, on Richter Transformation: New Data on a CAR T-Cell Treatment

Allison M. Winter, MD, of the Cleveland Clinic Taussig Cancer Institute, discusses real-world outcomes with lisocabtagene maraleucel in patients with Richter transformation, a difficult-to-treat population with a poor prognosis. Data from the Center for International Blood and Marrow Transplant Research showed this therapy provided clinical benefit with a high complete response rate (Abstract 7010).

Multiple Myeloma

Paula Rodríguez-Otero, MD, PhD, and Amrita Y. Krishnan, MD, on Multiple Myeloma: Moving BCMA-Directed Therapies to Earlier Use

Paula Rodríguez-Otero, MD, PhD, of Spain’s Cancer Center Clínica Universidad de Navarra, and Amrita Y. Krishnan, MD, of the City of Hope Cancer Center, discuss two key studies on B-cell maturation antigen (BCMA)-directed therapies: CARTITUDE-4 on ciltacabtagene autoleucel in patients with functional high-risk multiple myeloma; and DREAMM-7 on belantamab mafodotin-blmf plus bortezomib and dexamethasone vs daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory disease.

Breast Cancer

Reshma Jagsi, MD, DPhil, and Tarah J. Ballinger, MD, on Early-Stage Breast Cancer in Black Women: Docetaxel and Peripheral Neuropathy

Reshma Jagsi, MD, DPhil, of Emory University Winship Cancer Institute, and Tarah J. Ballinger, MD, of Indiana University Simon Comprehensive Cancer Center, discuss the disparate burden of taxane-induced peripheral neuropathy in Black women with early-stage breast cancer and how a tailored trial for this population showed that using docetaxel as the preferred taxane may be beneficial (LBA503).

Lymphoma

Yasmin H. Karimi, MD, on Diffuse Large B-Cell Lymphoma: Update on Use of Epcoritamab Plus Chemotherapy

Yasmin H. Karimi, MD, of the University of Michigan Comprehensive Cancer Center, discusses data reaffirming the efficacy and feasibility of using epcoritamab plus R-DHAX/C (rituximab, dexamethasone, cytarabine, and oxaliplatin or carboplatin) in autologous stem cell transplant–eligible patients with diffuse large B-cell lymphoma. Response rates were reported to be high, and most patients proceeded to transplant (Abstract 7032).

Skin Cancer

Georgina V. Long, MD, PhD, on BRAF-Mutated Melanoma: Long-Term Follow-up of Adjuvant Dabrafenib Plus Trametinib vs Placebo

Georgina V. Long, MD, PhD, of the Melanoma Institute Australia and The University of Sydney, discusses final results with up to 10 years’ follow-up data of the COMBI-AD study of patients with stage III BRAF-mutated melanoma who received adjuvant dabrafenib plus trametinib (Abstract 9500).

Advertisement

Advertisement




Advertisement